Homoharringtonine induces apoptosis and growth arrest in human myeloma cells
Authors:
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (7) , 1400-1406
Abstract
Homoharringtonine (HHT) is a plant alkaloid with antileukemic activity which is currently being used for treatment of acute and chronic leukemias. The present studies have evaluated the effect of HHT on proliferation and apoptosis in human myeloma cells. Myeloma cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) assay. Apoptotic cells and cell cycle were evaluated by flow cytometry. Level of caspase-8, caspase-9, caspase-3, and DNA repair enzyme poly (ADP-ribose) polymerase (PARP), were investigated using Western blot analysis. We found that HHT significantly inhibited the proliferation of human multiple myeloma (MM) cell lines and tumor cells from patients with relapsed refractory MM in a dose-dependent manner. HHT also induced apoptosis in myeloma cells as evidenced by flow cytometric detection of annexin V binding assay. This apoptotic process was associated with the activation of caspase-8, caspase-9, caspase-3 and PARP. The results also demonstrate that HHT potentiates dexamethasone-induced killing of MM cells. These findings indicate that HHT may be effective in the treatment of MM.Keywords
This publication has 21 references indexed in Scilit:
- A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaBritish Journal of Cancer, 2006
- Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemiaLeukemia, 2006
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignanciesCancer Treatment Reviews, 2005
- Multiple MyelomaNew England Journal of Medicine, 2004
- Homoharringtonine: A New Treatment Option for Myeloid LeukemiaHematology, 2004
- Bortezomib Treatment for Multiple MyelomaAnnals of Pharmacotherapy, 2003
- Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous LeukemiaBlood, 1999
- Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitorsLeukemia, 1997
- Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.Journal of Clinical Oncology, 1985